本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

NGM Biopharmaceuticals Inc

1.54
+0.0000
成交量:- -
成交額:370.46萬
市值:1.29億
市盈率:-0.89
高:1.54
開:1.54
低:1.54
收:1.54
資料載入中...
2024/04/05

交易所摘牌聲明

Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
2024/04/05

超過5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/04/05

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/04/05

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/04/05

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/04/05

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/04/05

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/04/05

重要事件披露

Form 8-K - Current report
2024/04/05

私有化交易

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
2024/04/05

私有化交易

Form SC 13E3/A - Going private transaction by certain issuers: [Amend]
2024/04/04

[修訂]年度報告

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
2024/03/23

SEC問詢函

Form CORRESP - Correspondence
2024/03/22

私有化交易

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
2024/03/22

私有化交易

Form SC 13E3/A - Going private transaction by certain issuers: [Amend]
2024/03/11

年度報告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2024/03/11

重要事件披露

Form 8-K - Current report
2024/03/08

私有化交易

Form SC 13E3 - Going private transaction by certain issuers
2024/03/08

私有化交易

Form SC TO-T - Tender offer statement by Third Party
2024/02/26

超過5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/02/26

重要事件披露

Form 8-K - Current report